Stockreport

EHA2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma [Yahoo! Finance]

Genmab A/S - American Depositary Shares  (GMAB) 
PDF Relapsed/refractory (R/R) FL has a progressively worsening prognosis with each subsequent relapse and no curative treatment options. The early results of the Phase II [Read more]